Free Trial Information
BioCentury | Jun 29, 2009
Clinical News

Vismed sodium hyaluronate opthalmic solution regulatory update

...eye syndrome in 2006 (see BioCentury, Jan. 16, 2006). Lantibio Inc , Chapel Hill, N.C. TRB Chemedica International S.A....
Read More
BioCentury | Jun 8, 2009
Clinical News

Vismed sodium hyaluronate opthalmic solution regulatory update

...treat dry eye syndrome (see BioCentury, Nov. 12, 2007). Lantibio Inc , Chapel Hill, N.C. TRB Chemedica International S.A....
Read More
BioCentury | Jan 8, 2009
Distillery Therapeutics

Indication: Transplantation

...cryopyrin-associated periodic syndromes (CAPS) and Muckle-Wells syndrome. Diacerein, an anthraquinone derivative that inhibits IL-1a from TRB Chemedica International S.A....
Read More
BioCentury | Sep 29, 2008
Product Development

Ophthalmic deals

...develop CellTran's corneal stem cell therapy delivered using plasma polymerization technology Nov 07 Lantibio/Alcon (NYSE:ACL)/ TRB Chemedica...
Read More
BioCentury | Nov 12, 2007
Company News

Lantibio, TRB Chemedica, Alcon Laboratories Inc. deal

...market Vismed in 2006 (see BioCentury, Jan. 16, 2006). Lantibio Inc , Chapel Hill, N.C. TRB Chemedica International S.A....
Read More
BioCentury | Oct 29, 2007
Company News

Gilead, TRB Chemedica infectious news

...$10.3 million) in damages. GILD declined to comment. Gilead Sciences Inc. (GILD), Foster City, Calif. TRB Chemedica International S.A....
Read More
BioCentury | Jan 22, 2007
Clinical News

Vismed: Phase III started

...Vismed from TRB Chemedica, which markets the product in Europe. Lantibio Inc , Chapel Hill, N.C. TRB Chemedica International S.A....
Read More
BioCentury | Jan 16, 2006
Company News

Lantibio Inc., TRB Chemedica International SA deal

...CF), for which it has U.S. Orphan Drug designation. Lantibio Inc. , Chapel Hill, N.C. TRB Chemedica...
Read More
BioCentury | Jan 13, 2006
Company News

Lantibio in-licenses TRB's Vismed

TRB Chemedica (Geneva, Switzerland) granted Lantibio (Chapel Hill, N.C.) exclusive U.S. rights to develop and market Vismed to treat dry eye syndrome. Financial terms were not disclosed. Lantibio expects to begin "late stage" studies of...
Read More
Items per page:
1 - 9 of 9
BioCentury | Jun 29, 2009
Clinical News

Vismed sodium hyaluronate opthalmic solution regulatory update

...eye syndrome in 2006 (see BioCentury, Jan. 16, 2006). Lantibio Inc , Chapel Hill, N.C. TRB Chemedica International S.A....
Read More
BioCentury | Jun 8, 2009
Clinical News

Vismed sodium hyaluronate opthalmic solution regulatory update

...treat dry eye syndrome (see BioCentury, Nov. 12, 2007). Lantibio Inc , Chapel Hill, N.C. TRB Chemedica International S.A....
Read More
BioCentury | Jan 8, 2009
Distillery Therapeutics

Indication: Transplantation

...cryopyrin-associated periodic syndromes (CAPS) and Muckle-Wells syndrome. Diacerein, an anthraquinone derivative that inhibits IL-1a from TRB Chemedica International S.A....
Read More
BioCentury | Sep 29, 2008
Product Development

Ophthalmic deals

...develop CellTran's corneal stem cell therapy delivered using plasma polymerization technology Nov 07 Lantibio/Alcon (NYSE:ACL)/ TRB Chemedica...
Read More
BioCentury | Nov 12, 2007
Company News

Lantibio, TRB Chemedica, Alcon Laboratories Inc. deal

...market Vismed in 2006 (see BioCentury, Jan. 16, 2006). Lantibio Inc , Chapel Hill, N.C. TRB Chemedica International S.A....
Read More
BioCentury | Oct 29, 2007
Company News

Gilead, TRB Chemedica infectious news

...$10.3 million) in damages. GILD declined to comment. Gilead Sciences Inc. (GILD), Foster City, Calif. TRB Chemedica International S.A....
Read More
BioCentury | Jan 22, 2007
Clinical News

Vismed: Phase III started

...Vismed from TRB Chemedica, which markets the product in Europe. Lantibio Inc , Chapel Hill, N.C. TRB Chemedica International S.A....
Read More
BioCentury | Jan 16, 2006
Company News

Lantibio Inc., TRB Chemedica International SA deal

...CF), for which it has U.S. Orphan Drug designation. Lantibio Inc. , Chapel Hill, N.C. TRB Chemedica...
Read More
BioCentury | Jan 13, 2006
Company News

Lantibio in-licenses TRB's Vismed

TRB Chemedica (Geneva, Switzerland) granted Lantibio (Chapel Hill, N.C.) exclusive U.S. rights to develop and market Vismed to treat dry eye syndrome. Financial terms were not disclosed. Lantibio expects to begin "late stage" studies of...
Read More
Items per page:
1 - 9 of 9